Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab with concurrent chemoradiotherapy for recurrent esophageal squamous cell carcinoma
ChiCTR2300079055Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shandong Cancer Hospital. Primary endpoints: Progression-free survival evaluated by investigators and Safety. Started Dec 2023; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2300079055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079055.